|

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

RECRUITINGSponsored by National Cancer Institute (NCI)
Actively Recruiting
SponsorNational Cancer Institute (NCI)
Started2014-03-25
Est. completion2100-01-01
Eligibility
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT02610413

Summary

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* European American patients with deoxyribonucleic acid (DNA) available and designated case or control
* Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
* Patients who did not develop hypertension following a full course of treatment with bevacizumab

Conditions3

Breast CancerBreast CarcinomaCancer

Locations1 site

Eastern Cooperative Oncology Group
Boston, Massachusetts, 02215
Bryan P. Schneider317-274-6473bpschnei@iupui.edu

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.